Key Takeaways
- Contracts transform the backlog, not the near-term P&L: Two multi-year agreements worth over ₹9,000 crore were signed, but both were already in the capex plan; the FY25 EBITDA guidance widened only modestly to ₹1,450-1,700 crore, reflecting stronger visibility rather than a step-change in earnings.
- Sequential recovery underway, led by discretionary demand: Revenue rose 18% QoQ and EBITDA improved ~15% sequentially as dyes, pigments and polymers rebounded, while agrochemicals and pharmaceuticals remain soft on lean customer inventories.
- Gross margin debate is a framing dispute, not a profit warning: Management rejects gross margin percentage as a metric, pointing instead to gross profit per kg stability; the compression this quarter came from product mix and a ₹10/kg benzene move, not structural pricing pressure.
- Operating leverage is the FY25 story: With volumes guided to grow 20-25% and fixed costs stabilised, management expects EBITDA margins to climb toward 18-20% as revenue approaches ₹9,000 crore, even without raw material tailwinds.
- What to watch next quarter: Whether agrochemical demand begins the promised QoQ improvement from Q4, the pace of discretionary recovery sustaining, and any update on Chlorotoluenes commissioning timeline now set for FY26.
The Two Contracts: Visibility, Not Reinvention
- Contract 1 (9-year, ₹3,000+ crore): Signed December 2023 with a global agrochemical major for a niche herbicide intermediate, this converts short-term business into a long-term commitment; capex is already aligned and contribution begins in the current fiscal, with FY25 at ~₹300 crore and FY26 onwards at ₹350 crore+ at full ramp-up.
- Contract 2 (4-year, ₹6,000+ crore): With a multinational conglomerate for a specialty chemical already supplied for years, volumes will double in CY24 vs CY23, driving revenue from ~₹900 crore in FY24 to ₹1,500 crore in FY25 with no additional capex required.
- Guidance impact was visibility, not accretion: Both contracts were already embedded in the existing capex program and prior guidance; the FY25 EBITDA range widened from ₹1,450-1,600 crore to ₹1,450-1,700 crore, reflecting stronger confidence rather than new earnings.
- Contractual mix shifts to 30-40%: With these two agreements, the contractual portion of the portfolio reaches 30-40%, with the remainder described as semi-contractual with good visibility, reducing spot exposure.
Rajendra Gogri: "We are more than happy that this has come though in such a challenging macro environment which underscores our commitment to transforming relationships into sustainable long-term opportunities."
Demand Environment: A Two-Speed Recovery
- Discretionary has turned first: Products serving dyes, pigments, additives and polymers saw a rebound in Q3, shifting the end-user mix to ~60% discretionary vs ~40% non-discretionary, compared to a prior 50:50 split; management expects further improvement sequentially.
- Agrochemicals and pharma still soft: Major customers are managing lean inventories due to high carrying costs and moderated demand; buying patterns have become molecule-specific, with some products seeing sudden demand drops when their annual buying window arrived in 2024.
- US leads geographically: Volume recovery is better in the US, while domestic demand is described as "very steady"; products are exported to the US, Europe and Japan with finished goods sold worldwide.
- Non-regular market share declining: As demand recovers in regular channels, the share of non-regular markets is decreasing, a normalisation management welcomes.
- Pricing pressure should ease: Management expects that as global demand improves and product-specific recovery takes hold, both pricing and margins will improve, though no percentage quantification was offered.
- Red Sea disruption is manageable: Container pricing has moved up with a quarter or month lag to pass through to customers, who have been cooperative; 25-30% of exports go to Europe/US, but credits are from BL date so working capital impact may not be significant.
Margins: The Gross Profit Per Kg Framework
- Management rejects gross margin percentage as a metric: The company states it "never even evaluate[s] our business model" on gross margin percentage, focusing instead on gross profit per kg for each product, which tends to show more stability.
- Q3 compression explained by mix and benzene: Gross margin percentage fell to its lowest in eight quarters due to product mix shifts and a benzene price increase from ₹70 to ₹80; management sees no significant increase in pricing pressure.
- Simple per-kg math doesn't work: An analyst's computation showing gross profit per kg 20-25% below historical levels was dismissed because many products are captively consumed into value-added downstream products, making a simple division of volume into gross profit misleading.
- Absolute gross profit driven by volumes: Substantial improvement in absolute gross profit will be volume-led, though per-kg improvement is also expected as volume pressure eases.
- Contract 2 margins are not a compromise: The 15-17% margin range reflects raw material price levels; management states the same product could show 20%+ margins if raw material prices fall, and 12% if they rise, with the focus on per-kg profitability at current raw material levels.
Rajendra Gogri: "On gross margin we never even evaluate our business model. Basically, it is always gross profit per kg for a particular product. This is the major criteria for us."
Operating Leverage & The Path to 18-20% Margins
- The math: At ₹9,000 crore turnover, EBITDA margins are expected to reach 18-20% as operating leverage kicks in and conversion of gross profit to EBITDA becomes high; with constant raw material prices, EBITDA percentage should progressively rise.
- FY24 base: EBITDA is expected to close closer to ₹1,000 crore, revised up from the earlier ₹950-1,000 crore range.
- FY25 bridge: Revenue growth of 20-25% on a composite volume basis, plus stabilised fixed costs, drives the guided ₹1,450-1,700 crore EBITDA; after that volume growth, headroom remains for another 10-15% volume expansion in zones 1, 2 and 3 assets.
- Capex deployment on track: ₹860 crore deployed in 9M FY24; FY24 total expected at ₹1,200-1,300 crore, with the balance of the ₹2,500-3,000 crore plan falling in FY25; all existing site expansions (Vapi, current Jhagadia, Dahej) to be completed in calendar year 2024.
Rajendra Gogri: "Yes, that's what we have been highlighting for a year or so because the operating leverage will kick in and conversion of gross profit to EBITDA will be high and that with the constant raw material prices, our EBITDA as a percentage also progressively should go up."
Chlorotoluenes: The FY27 Catalyst
- Timeline: Commissioning will happen in FY26, with FY26 being the commissioning year; sizable EBITDA is expected from FY27 onwards.
- Economics: The chain carries an EBITDA margin of 25-30% and a revenue target of ₹2,000 crore plus; the product will serve as an import substitute within India and for export markets.
- Strategic positioning: The project introduces a new value chain (Chlorotoluenes) alongside ongoing capacity increases in Ethylation and Nitrotoluene, all progressing well and set for phased commissioning from FY25.
Balance Sheet & Capital Allocation
- FY25 gross debt: Expected in the range of ₹3,500-3,800 crore, assuming raw material prices remain at current levels.
- Tax rate: Expected at 15-17% for FY25.
- Asset turnover on Contract 2: Management declined to provide a ballpark number for the ₹1,500 crore revenue plant, stating those numbers were not immediately available.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY24 EBITDA | Closer to ₹1,000 crore (revised from ₹950-1,000 crore) | FY24 close |
| FY25 EBITDA | ₹1,450-1,700 crore | FY25 |
| FY25 volume growth | 20-25% on composite basis | FY25 |
| EBITDA margin target | 18-20% when revenue reaches ~₹9,000 crore | At ~₹9,000 cr revenue |
| Demand normalisation | Widespread recovery across segments | Next 1-2 quarters |
| Agrochemical recovery | Progressive QoQ improvement starting Q4 FY24 | Q4 FY24 onwards |
| Discretionary demand | Further improvement expected | Q4 FY24 onwards |
| Chlorotoluenes commissioning | Phased commissioning begins | FY26 |
| Chlorotoluenes EBITDA contribution | Sizable EBITDA expected | FY27 onwards |
| Contract 2 revenue ramp | ₹1,500 crore (from ~₹900 crore in FY24) | FY25 |
| Contract 1 revenue ramp | ~₹300 crore in FY25, ₹350 crore+ at full run-rate | FY25 / FY26+ |
| Capex deployment | ₹2,500-3,000 crore total between FY24-FY25 | FY24-FY25 |
| Existing site expansions completion | Vapi, current Jhagadia, Dahej | Calendar year 2024 |
| FY25 gross debt | ₹3,500-3,800 crore (assuming stable RM prices) | FY25 |
| FY25 tax rate | 15-17% | FY25 |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Consolidated revenue | ₹1,889 cr, +18% QoQ |
| Consolidated EBITDA (incl. other income) | ₹268 cr, +15% QoQ |
| Profit after tax | ₹124 cr, +36% QoQ |
| EBITDA margin | ~14.2% (₹268 cr on ₹1,889 cr, per an analyst's math); management expects movement toward 18–20% at higher turnover |
| FY24 EBITDA guidance | ~₹1,000 cr, revised from ₹950–1,000 cr earlier |
| FY25 EBITDA guidance | ₹1,450–1,700 cr |
| 9M FY24 CAPEX | ₹860 cr |
| FY24–FY25 planned CAPEX | ₹2,500–3,000 cr combined |
| Nitrochlorobenzene production | 19,580 MT, vs 18,199 MT YoY and 19,014 MT QoQ |
| Hydrogenation production | 3,644 TPM, vs 2,995 TPM YoY and 3,136 TPM QoQ |
| Nitro-Toluene production | 6,951 MT, vs 7,528 MT YoY and 7,560 MT QoQ |
| PDA volume | 481 tonnes per month |
| Discretionary vs non-discretionary mix | ~60% discretionary, ~40% non-discretionary; prior period ~50:50 |
| FY25 volume growth target (composite) | 20–25% |
| Long-term agrochemical contract revenue potential | Over ₹3,000 cr over 9 years; FY25 ~₹300 cr, FY26 onwards ₹350 cr+ |
| 4-year specialty chemical contract value | Over ₹6,000 cr; FY24 to FY25 revenue jump from ~₹900 cr to ₹1,500 cr |
| Chlorotoluene chain revenue target | ₹2,000 cr plus; EBITDA margin 25–30% |
| FY25 estimated gross debt | ₹3,500–3,800 cr |
| FY25 estimated tax rate | 15–17% |